Evidence map›Paper›PMID 40183931›Full record

ArticleWorld journal of urology2025

Pharmacotherapy for overactive bladder syndrome and the risk of incident dementia.

David Sheyn, Jennifer Murphy, Abhimanyu Mahajan, C Emi Bretschneider, Lindsay Scott, Stephen Rhodes, Adonis Hijaz, Ankita Gupta

Abstract readComparative Study
PubMed Publisher
In one paragraph

Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

David SheynUrology Institute, University Hospitals, Cleveland, OH, USA. David.d.sheyn@gmail.com.
Jennifer MurphyResearch and Education Institute, University Hospitals, Cleveland, OH, USA.
Abhimanyu MahajanDepartment of Neurology, University of Cincinnati, Cincinnati, OH, USA.
C Emi BretschneiderDepartment of Obstetrics and Gynecology, Division of Female Pelvic Medicine and Reconstructive Surgery, Northwestern University, Chicago, IL, USA.
Lindsay ScottCenter for Brain Health, Cleveland Clinic, Cleveland, OH, USA.
Stephen RhodesUrology Institute, University Hospitals, Cleveland, OH, USA.
Adonis HijazUrology Institute, University Hospitals, Cleveland, OH, USA.
Ankita GuptaDepartment of Obstetrics and Gynecology, Division of Female Pelvic Medicine and Reconstructive Surgery, University of Louisville, Louisville, KY, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeTo compare the risk of incident dementia in patients prescribed either an anticholinergic medication or mirabegron. MATERIALS AND

methodsThis was a retrospective cohort study of patients treated for OAB with pharmacotherapy between the years 2012 and 2023, using data from the TrinetX Research Collaborative Network. Patients who were diagnosed with OAB who were prescribed Mirabegron, Oxybutynin, Tolterodine, Darifenacin, Trospium, Fesoterodine, or Solifenacin after 1/1/2012 were identified. Anticholinergic medications were stratified into high-risk (Oxybutynin, Tolterodine, and Solifenacin) and low-risk (Darifenacin, Trospium and Fesoterodine) Patients with OAB who were not prescribed medications were included as a control group. The primary outcome was incidence of dementia occurring after initiation of pharmacotherapy or entry into the study (for the control group). Using Cox proportional hazard analyses, and adjusting for age and sex and adjusting for Elixhauser comorbidity index, anticholinergic burden score, and the average treatment effect, the risk of each medication on incident dementia was determined.

resultsA total of 941,402 met inclusion for the final analysis, with 83,550 prescribed any medication. With an average follow-up time of 4.3 years, the only medication not found to be associated with an increased risk of dementia in any group was fesoterodine, while mirabegron was found to have a significant association with dementia across all age groups for both sexes.

conclusionsMost anticholinergic medications and mirabegron are associated with an increased risk of dementia compared to untreated controls with OAB, while fesoterodine was not found to be associated with an increased risk in any group.

Indexed as

Cholinergic AntagonistsDementiaMuscarinic AntagonistsUrinary Bladder, OveractiveUrological AgentsAcetanilidesAgedAged, 80 and overCohort StudiesFemaleHumansIncidenceMaleMiddle AgedRetrospective StudiesThiazolesAcetanilidesCholinergic AntagonistsmirabegronMuscarinic AntagonistsThiazolesUrological AgentsAnti-cholinergic medicationsDementiaMirabegronOAB

Identifiers

PMID40183931

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.